The Early Detection of Cancer Conference 2023

Learn about our new 5-letter sequencing technology – duet multiomics solution +modC – and discover the combinatorial power of genetics and epigenetics.

10 October 2023
to 12 October 2023

Central Hall Westminster, London

About the event

Cancer Research UK, Canary Center at Stanford, and OHSU Knight Cancer Institute present the Early Detection of Cancer Conference series. The annual conference brings together experts in early detection from multiple disciplines to share groundbreaking research and progress in the field.

The Conference is part of a long-term commitment to invest in early detection research, to understand the biology behind early-stage cancers, find new detection and screening methods, and enhance uptake and accuracy of screening.

Join us from 10–12 October for this year’s conference which is jam-packed with engaging discussions, lightning talks from submitted abstracts and opportunities to network with experts from across the globe. We’ll also see the return of our ‘Great Debates’ as our speakers go head-to-head to debate provocative early detection challenges.

2023 session topics include:

  • Inequalities in cancer detection and diagnosis
  • Risk stratification to inform early detection
  • Understanding pre-cancers to enable early detection
  • Multicancer early detection – beyond ctDNA

One sample. One workflow. One solution.

Here are the relevant biomodal resources for information. Find poster presentation information, case studies, interviews, and more.

Related resources

Refining liquid biopsy: generating more information from cell free DNA

Refining liquid biopsy: generating more information from cell-free DNA

Learn how duet multiomics solution +modC is transforming research efforts in early cancer detection, risk stratification, and disease monitoring by using liquid biopsy for profiling of cfDNA. This poster illustrates how capturing complete genetic and epigenetic information in one workflow, from a single low-volume DNA sample is more powerful for early disease detection than either alone.

Attending from biomodal

Director of Sales and Business Development, Europe
Early Detection of Cancer Conference Oct 23

Get in touch

Cambridge Epigenetix is now biomodal